KRYS
Price
$125.05
Change
-$1.63 (-1.29%)
Updated
May 23 closing price
Capitalization
3.61B
79 days until earnings call
VKTX
Price
$26.98
Change
-$0.75 (-2.70%)
Updated
May 23 closing price
Capitalization
3.03B
60 days until earnings call
Interact to see
Advertisement

KRYS vs VKTX

Header iconKRYS vs VKTX Comparison
Open Charts KRYS vs VKTXBanner chart's image
Krystal Biotech
Price$125.05
Change-$1.63 (-1.29%)
Volume$298.65K
Capitalization3.61B
Viking Therapeutics
Price$26.98
Change-$0.75 (-2.70%)
Volume$1.81M
Capitalization3.03B
KRYS vs VKTX Comparison Chart
Loading...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VKTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KRYS vs. VKTX commentary
May 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KRYS is a Hold and VKTX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
May 24, 2025
Stock price -- (KRYS: $125.05 vs. VKTX: $26.98)
Brand notoriety: KRYS and VKTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KRYS: 86% vs. VKTX: 46%
Market capitalization -- KRYS: $3.61B vs. VKTX: $3.03B
KRYS [@Biotechnology] is valued at $3.61B. VKTX’s [@Biotechnology] market capitalization is $3.03B. The market cap for tickers in the [@Biotechnology] industry ranges from $298.89B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KRYS’s FA Score shows that 0 FA rating(s) are green whileVKTX’s FA Score has 0 green FA rating(s).

  • KRYS’s FA Score: 0 green, 5 red.
  • VKTX’s FA Score: 0 green, 5 red.
According to our system of comparison, VKTX is a better buy in the long-term than KRYS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KRYS’s TA Score shows that 4 TA indicator(s) are bullish while VKTX’s TA Score has 5 bullish TA indicator(s).

  • KRYS’s TA Score: 4 bullish, 4 bearish.
  • VKTX’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, VKTX is a better buy in the short-term than KRYS.

Price Growth

KRYS (@Biotechnology) experienced а -4.25% price change this week, while VKTX (@Biotechnology) price change was -5.10% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.22%. For the same industry, the average monthly price growth was +3.23%, and the average quarterly price growth was -2.73%.

Reported Earning Dates

KRYS is expected to report earnings on Aug 11, 2025.

VKTX is expected to report earnings on Jul 23, 2025.

Industries' Descriptions

@Biotechnology (+1.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KRYS($3.61B) has a higher market cap than VKTX($3.03B). KRYS YTD gains are higher at: -20.177 vs. VKTX (-32.952). KRYS has higher annual earnings (EBITDA): 140M vs. VKTX (-171.93M). VKTX has more cash in the bank: 852M vs. KRYS (617M). VKTX has less debt than KRYS: VKTX (1M) vs KRYS (9.66M). KRYS has higher revenues than VKTX: KRYS (333M) vs VKTX (0).
KRYSVKTXKRYS / VKTX
Capitalization3.61B3.03B119%
EBITDA140M-171.93M-81%
Gain YTD-20.177-32.95261%
P/E Ratio29.99N/A-
Revenue333M0-
Total Cash617M852M72%
Total Debt9.66M1M966%
FUNDAMENTALS RATINGS
KRYS vs VKTX: Fundamental Ratings
KRYS
VKTX
OUTLOOK RATING
1..100
5319
VALUATION
overvalued / fair valued / undervalued
1..100
69
Overvalued
44
Fair valued
PROFIT vs RISK RATING
1..100
4572
SMR RATING
1..100
5734
PRICE GROWTH RATING
1..100
8963
P/E GROWTH RATING
1..100
97100
SEASONALITY SCORE
1..100
2n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VKTX's Valuation (44) in the Biotechnology industry is in the same range as KRYS (69) in the Pharmaceuticals Major industry. This means that VKTX’s stock grew similarly to KRYS’s over the last 12 months.

KRYS's Profit vs Risk Rating (45) in the Pharmaceuticals Major industry is in the same range as VKTX (72) in the Biotechnology industry. This means that KRYS’s stock grew similarly to VKTX’s over the last 12 months.

VKTX's SMR Rating (34) in the Biotechnology industry is in the same range as KRYS (57) in the Pharmaceuticals Major industry. This means that VKTX’s stock grew similarly to KRYS’s over the last 12 months.

VKTX's Price Growth Rating (63) in the Biotechnology industry is in the same range as KRYS (89) in the Pharmaceuticals Major industry. This means that VKTX’s stock grew similarly to KRYS’s over the last 12 months.

KRYS's P/E Growth Rating (97) in the Pharmaceuticals Major industry is in the same range as VKTX (100) in the Biotechnology industry. This means that KRYS’s stock grew similarly to VKTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KRYSVKTX
RSI
ODDS (%)
Bullish Trend 3 days ago
89%
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
78%
Momentum
ODDS (%)
Bearish Trend 3 days ago
76%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bearish Trend 3 days ago
77%
Bearish Trend 3 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
74%
Bullish Trend 3 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
75%
Bullish Trend 3 days ago
84%
Advances
ODDS (%)
Bullish Trend 6 days ago
77%
Bullish Trend 9 days ago
82%
Declines
ODDS (%)
Bearish Trend 3 days ago
76%
Bearish Trend 11 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
77%
Bearish Trend 3 days ago
78%
Aroon
ODDS (%)
Bearish Trend 3 days ago
79%
Bullish Trend 3 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VKTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CLFFX19.71N/A
N/A
Clifford Capital Partners Investor
RAIWX26.18N/A
N/A
Manning & Napier Rainier Intl Discv W
RLBAX34.49-0.05
-0.14%
American Funds American Balanced R1
VMFGX433.15-0.72
-0.17%
Vanguard S&P Mid-Cap 400 Growth Idx I
PMEGX57.73-0.39
-0.67%
T. Rowe Price Instl Mid-Cap Equity Gr